Bio-Rad Laboratories (NYSE:BIO) Price Target Raised to $330.00 at Citigroup

Bio-Rad Laboratories (NYSE:BIO) had its price objective raised by investment analysts at Citigroup from $300.00 to $330.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. Citigroup’s target price points to a potential downside of 4.73% from the company’s current price.

Several other equities research analysts have also recently commented on BIO. Wells Fargo & Company lifted their target price on Bio-Rad Laboratories from $310.00 to $330.00 and gave the company an “equal weight” rating in a research note on Wednesday. Weiss Ratings reissued a “sell (d)” rating on shares of Bio-Rad Laboratories in a research note on Monday. Royal Bank Of Canada lifted their price objective on Bio-Rad Laboratories from $320.00 to $370.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Zacks Research cut Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Bio-Rad Laboratories currently has a consensus rating of “Reduce” and an average price target of $343.33.

Bio-Rad Laboratories Price Performance

NYSE:BIO traded up $13.50 during mid-day trading on Wednesday, reaching $346.38. 318,734 shares of the company were exchanged, compared to its average volume of 329,214. The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12. The stock has a market cap of $9.27 billion, a PE ratio of 56.91 and a beta of 1.06. Bio-Rad Laboratories has a 12 month low of $236.73 and a 12 month high of $352.63. The company has a fifty day moving average of $301.02 and a 200 day moving average of $287.81.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Tuesday, August 4th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.75 by $0.87. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The company had revenue of $651.00 million for the quarter, compared to analyst estimates of $623.99 million. During the same period in the prior year, the business earned $2.61 earnings per share. Bio-Rad Laboratories’s quarterly revenue was down .1% on a year-over-year basis. On average, research analysts anticipate that Bio-Rad Laboratories will post 9.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Massachusetts Financial Services Co. MA increased its holdings in shares of Bio-Rad Laboratories by 4,534.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 399,207 shares of the medical research company’s stock worth $120,956,000 after acquiring an additional 390,593 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Bio-Rad Laboratories by 2,271.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 397,171 shares of the medical research company’s stock valued at $111,363,000 after purchasing an additional 380,422 shares in the last quarter. Boston Partners acquired a new position in shares of Bio-Rad Laboratories in the 4th quarter valued at approximately $75,037,000. Assenagon Asset Management S.A. grew its position in shares of Bio-Rad Laboratories by 6,586.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 147,834 shares of the medical research company’s stock valued at $41,209,000 after purchasing an additional 145,623 shares during the period. Finally, Norges Bank bought a new stake in Bio-Rad Laboratories during the 4th quarter worth approximately $34,600,000. 65.24% of the stock is owned by institutional investors and hedge funds.

More Bio-Rad Laboratories News

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Bio-Rad reported second-quarter EPS of $2.62, exceeding the $1.75 MarketBeat consensus estimate and the $2.34 Zacks estimate. Revenue of $651 million also surpassed expectations of approximately $624 million, supporting the positive reaction. MarketBeat earnings report
• Positive Sentiment: Results included improved gross profit, $98.7 million in operating cash flow and $517 million in cash. Reported net income and diluted EPS were also boosted by substantial items, so investors may focus more closely on the quality and sustainability of the earnings beat. Quiver Quantitative earnings article
• Positive Sentiment: Royal Bank of Canada raised its BIO price target from $320 to $370 and maintained an “outperform” rating, signaling additional upside following the earnings release. Benzinga analyst action
• Neutral Sentiment: Bio-Rad issued third-quarter 2026 results guidance, though the available report does not provide the specific forecast details. Bio-Rad third-quarter outlook
• Negative Sentiment: Full-year 2026 revenue guidance of $2.5 billion to $2.6 billion is at or below the $2.6 billion consensus estimate, limiting the impact of the quarterly beat. Revenue was also essentially flat year over year. Bio-Rad guidance report
• Negative Sentiment: The company plans to cut jobs and close facilities, indicating cost-reduction efforts but also highlighting pressure on demand, margins or operational efficiency. MarketWatch restructuring article
• Negative Sentiment: Wells Fargo raised its target from $310 to $330 but retained an “equal weight” rating, leaving its target below the current trading level and signaling limited near-term upside in its view. Benzinga analyst action

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.